|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Arkansas Cancer Research Center, Departments
of Pathology and Anatomy & Neurobiology, and the Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences,
Little Rock.
Syndecan-1 (CD138) is a transmembrane heparan sulfate-bearing
proteoglycan expressed by most myeloma plasma cells that regulates adhesion, migration, and growth factor activity. In patients with myeloma, shed syndecan-1 accumulates in the bone marrow, and high levels of syndecan-1 in the serum are an indicator of poor prognosis. To test the effect of soluble syndecan-1 on tumor cell growth and
dissemination, ARH-77 B-lymphoid cells were engineered to produce a
soluble form of syndecan-1. Controls included vector only
(neo)-transfected cells and cells transfected with full-length syndecan-1 complementary DNA that codes for the cell surface form of
syndecan-1. Assays reveal that all 3 transfectants have similar growth
rates in vitro, but cells expressing soluble syndecan-1 are
hyperinvasive in collagen gels relative to controls. When injected into
the marrow of human bones that were implanted in severe combined
immunodeficient mice, tumors formed by cells expressing soluble
syndecan-1 grow faster than tumors formed by neo-transfected cells or
by cells expressing cell surface syndecan-1. In addition, cells bearing
cell surface syndecan-1 exhibit a diminished capacity to establish
tumors within the mice as compared with both neo- and soluble
syndecan-1-transfected cells. Tumor cell dissemination to a
contralateral human bone is detected significantly more often in the
tumors producing soluble syndecan-1 than in controls. Thus, high levels
of soluble syndecan-1 present in patients with myeloma may contribute
directly to the growth and dissemination of the malignant cells and
thus to poor prognosis.
(Blood. 2002;100:610-617) The syndecans are a family of heparan
sulfate-bearing proteoglycans that are expressed on the surfaces of
many cell types.1,2 Their functions at the cell surface
have been extensively characterized and include promotion of growth
factor interaction and activity as well as cell-cell and
cell-extracellular matrix adhesion. Expression of syndecans is often
altered in cancer, and several studies suggest that loss of syndecan-1
expression in carcinomas accompanies the malignant
phenotype.3,4 It has been suggested that this loss of
syndecan-1 expression renders the tumor cells less adhesive, thereby
increasing their potential to metastasize. However, in other cancers,
such as adenocarcinoma of the pancreas and multiple myeloma, syndecan-1
expression on the cell surface remains high even though these tumors
disseminate to sites distal from the primary tumor.5,6
In addition to being present at the cell surface, like some other
membrane proteins, syndecans can be cleaved from the cell surface and
released into the extracellular space by the action of
secretases.7 The specific enzyme responsible for the
shedding of syndecan-1 from the cell surface has not been identified,
but its activity is inhibited by an inhibitor of
metalloprotease-3.8 The proteolytically released
extracellular domain (ectodomain) of syndecan-1 retains its
biologically active heparan sulfate chains. For example, soluble
syndecan-1 ectodomain from wound fluids binds to fibroblast growth
factor-2 (FGF-2) and inhibits its mitogenicity, but
subsequent degradation of the ectodomain heparan sulfate chains with
platelet heparanase produces heparan sulfate fragments that activate
FGF-2 mitogenicity.9 Thus, soluble syndecan-1 ectodomain
can regulate the activity of growth factors.
To examine the role of soluble syndecans in cancer, initial studies
were launched to determine if detectable levels of soluble syndecan-1
ectodomain are present in the serum of patients with multiple myeloma.
We were first to report that some patients had relatively high levels
of soluble syndecan-1 ectodomain in their serum and that these high
levels correlated with high tumor burden and other markers of disease
severity, including beta-2 microglobulin.10 Subsequent
studies by others on a large population of patients with myeloma found
that high levels of soluble syndecan-1 ectodomain in the serum
correlated with a poor disease prognosis.11 Patients with
high serum syndecan-1 had a median survival of 20 months, whereas those
with low serum syndecan-1 had a median survival of 44 months. Very high
levels of soluble syndecan-1 ectodomain (median concentration, 900 ng/mL) are also present in bone marrow aspirates obtained from patients
with myeloma, where it binds to hepatocyte growth factor and regulates
the biologic activity of this and possibly other
cytokines.12
Although high levels of soluble syndecan-1 ectodomain correlate with
poor prognosis in myeloma, it is not known if the ectodomain plays a
direct role in promoting disease severity or if the high levels of
syndecan-1 are simply a reflection of an aggressive tumor. For example,
the high levels of soluble syndecan-1 ectodomain could be due to
constitutive shedding by a large tumor mass. Alternatively, high levels
of soluble ectodomain could result from tumors having high levels of
protease activity. In contrast to in vivo findings raising the
possibility that soluble syndecan-1 may promote tumor growth, in vitro
studies have demonstrated that soluble syndecan-1 can inhibit growth of
both carcinoma and myeloma cells.13,14 To clarify the role
of soluble syndecan-1 and to determine if soluble syndecan-1 ectodomain
has a direct effect on tumor growth and dissemination, we compared the
behavior of cells that secrete high levels of soluble syndecan-1 with
those that express syndecan-1 at their cell surface.
ARH-77 cells were established from a patient with a plasma cell
leukemia and selected as a model for our studies because these cells
lack syndecan-1 expression.14 Moreover, these cells have been previously used as a model for multiple myeloma and shown to grow
within, and disseminate to, human fetal bones implanted in severe
combined immunodeficient (SCID) mice (SCID-hu mice).15 ARH-77 cells were transfected with a complementary DNA (cDNA) encoding
the full-length syndecan-1 core protein or with a truncated construct
lacking the coding region for the transmembrane and cytoplasmic domains
of syndecan-1. Transfection with this truncated form of syndecan-1
results in cells that express and secrete high levels of soluble
syndecan-1 ectodomain. We find that in vitro these cells grow at a
similar rate to controls, including neo-transfected ARH-77 cells or to
cells that express cell surface syndecan-1. However, in the SCID-hu
mouse, tumors formed by cells producing high levels of the soluble
syndecan-1 ectodomain grow significantly faster than control cells. In
addition, both in vitro and in vivo results indicate that the soluble
syndecan-1 ectodomain promotes dissemination of the tumor cells.
Cells and cell culture
Cell growth assay
Cell invasion assay The percentage of invasive cells was determined as previously described.16 Briefly, 5.0 × 104 cells were placed on the surface of a hydrated type I collagen gel (0.5 mg/mL; BD Biosciences, Bedford, MA) in complete media and returned to the cell culture incubator. Forty-eight hours later, a trypsin digestion followed by a limited collagenase digestion was used to release the attached "noninvasive" cells, and then complete collagenase digestion was used to release and recover the invasive cells. The number of noninvasive versus invasive cells was quantified by using a Coulter counter.Affinity coelectrophoresis, Western blotting, and dot blotting Purification of syndecan-1, affinity coelectrophoresis (ACE) gels, and Western blotting procedures were performed as previously described.18 Briefly, 35S-labeled syndecan-1 was purified from media conditioned by cells with the use of DEAE isolation followed by affinity purification with antibody 281.2. For ACE, the purified samples were analyzed on a 1% agarose gel having 9 parallel lanes of agarose containing decreasing amounts of type I collagen. Following imaging with the use of a PhosphorImager, an apparent Kd of the sample for collagen can be determined by the concentration range within which a shift in proteoglycan mobility occurs. For Western blots, affinity-purified syndecan-1 was run on 4% to 12% Tris-glycine gels, transferred to a cationic nylon filter, and detected by using 125I-labeled antibody 281.2. For immunodot blotting, samples were brought to pH 4.5, blotted onto a cationic nylon filter, and probed with 125I-labeled antibody 281.2 as previously described.16Growth of tumors in SCID-hu mice Seven-week-old homozygous CB.17 scid/scid mice (SCID) were obtained from Harlan Sprague Dawley (Indianapolis, IN) and were housed and monitored in our animal facility. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee. Implantation of human femur grafts into SCID mice to produce SCID-hu mice has been previously described.19,20 Briefly, the femora were cut into halves (approximately 5 × 5 × 10 mm) and implanted subcutaneously into both sides of SCID mice. Six weeks after implantation of bone, 1 × 105 cells were injected directly into the marrow cavity of one of the fetal bones implanted in the SCID-hu host. Murine sera were collected at biweekly intervals, and the levels of human immunoglobulin kappa light chain were assessed as an indicator of tumor growth. When the animals were killed, differences in mean tumor diameter, mean tumor weight, and mean sera kappa level among the experimental groups were compared by the Student t test, and P values were reported (P .05 was
considered statistically significant).
Determination of kappa light chain levels in SCID-hu serum The levels of human immunoglobulin kappa light chain were determined by enzyme-linked immunosorbent assay (ELISA).20 Plates were coated with 50 µL/well of primary antihuman kappa light chain (5 µg/mL; The Binding Site, San Diego, CA) and incubated overnight at 4°C. The plates were washed 3 times in phosphate-buffered saline (PBS) containing 1% (vol/vol) of Tween 20. A 50-µL sample diluted in PBS was added, and the plates were incubated at room temperature for 2 hours. After washing 3 times with PBS/Tween 20, 50 µL biotinylated antibody (affinity-purified antihuman kappa light chain at 0.5 µg/mL) was added to each well for 1 hour. The plates were then washed, and 50 µL streptavidinhorseradish peroxidase was added to each well and allowed to bind for 30 minutes. After a final wash, 50 µL ortho-phenylenediamine solution (2 tablets ortho-phenylenediamine in 6 mL 0.1 M citric acid/Phughyte; Dako, Carpinteria, CA) containing 3% H2O2 was added, and the color was allowed to develop for 3 to 5 minutes. The reaction was stopped by adding 100 µL 0.5M H2SO4, and the absorbance was read at 450 nm on an Auto-Reader II ELISA reader (Ortho Diagnostic Systems, Raritan, NJ). All samples were analyzed in duplicate simultaneously to preclude interassay variability. The standard curve was linear between 0.35 and 300 ng/mL, and samples were diluted to concentrations within this range.Flow cytometry For confirmation of the phenotype of the primary tumor and determination of tumor cell dissemination to other organs, fresh tissues, including the bone injected with tumor cells and the uninjected contralateral bone, spleen, liver, femora, and vertebrae, were excised after mice were killed. Organs were cut in halves, of which one was fixed in 10% formalin, and the other was separated into a single-cell suspension in PBS. For flow cytometry, cell suspensions were washed in PBS and stained with either antibodies to human syndecan-1 (CD138-fluorescein isothiocyanate [FITC]; Serotec), murine syndecan-1 (281.2-FITC),21 or human CD38-FITC/CD45-phycoerythrin (PE; BD Immunocytometry Systems, San Jose, CA). To identify nonviable cells, the cells were incubated with 0.4 mL PBS and 4 µL 2 mg/mL propidium iodide (for CD138 and 281.2 staining) or 20 µL 25 µg/mL 7-amino actinomycin D (7-AAD) (for CD38/45 staining). Samples were analyzed by using a FACScan flow cytometer (Becton Dickinson).Histopathologic and immunocytochemical analysis Bones were decalcified with 10% EDTA pH 7.0 prior to embedding, and all fixed tissues were embedded in paraffin, sectioned, and stained with hematoxylin and eosin. For immunochemical staining, sections were deparaffinized in xylene and rehydrated through graded concentrations of ethanol and distilled water. Slides were washed and incubated with 3% H2O2 for 5 minutes to block endogenous peroxidase, then incubated with blocking serum for 10 minutes. Rabbit antihuman kappa light chain (1:250) and biotinylated universal antibody and streptavidin/peroxidase complex (Universal Quick Kit; Vector Laboratories) were used following the manufacturer's instruction. Tissues were considered positive for metastasis of tumor if clear foci of kappa light chain-positive tumor cells were found in at least 2 nonoverlapping areas. Slides were analyzed independently by 2 investigators who did not know the identity of the mice. Staining of syndecan-1 within tissues used monoclonal antibody 281.2, biotinylated rabbit antirat, and the Vector Laboratories (Burlingame, CA) avidin-biotin complex kit. Between each step in all the immunohistochemical staining procedures, slides were rinsed 3 times with PBS. Peroxidase staining was visualized with DAB (3,3'-diaminobenzidine; Vector Laboratories) solution until desired stain intensity developed. Sections were rinsed in tap water and were lightly counterstained in Mayer hematoxylin.
To determine the effects of soluble syndecan-1 ectodomain on tumor
cell behavior, ARH-77 cells were transfected with a cDNA coding for the
syndecan-1 extracellular domain, but lacking the transmembrane and
cytoplasmic domains. This form of syndecan-1 does not anchor within the
cell membrane and is secreted into the culture media. This action is in
contrast to cells that produce wild-type syndecan-1 that is anchored to
the cell surface and can be enzymatically shed, thereby releasing an
intact ectodomain into the culture media. Following selection in G418,
cells were cloned by limiting dilution and expanded, and 2 clones
producing soluble syndecan-1 ectodomain were identified by immunodot
blots of conditioned cell culture medium (not shown). Over a 72-hour period, high levels of syndecan-1 accumulate in the media from these 2 clonal cell lines as compared with vector-only transfected cells or
cells transfected with full-length syndecan-1 cDNA that codes for the
cell surface form of the proteoglycan
(Figure 1).
Characterization of soluble syndecan-1 ectodomain Western blotting of soluble syndecan-1 ectodomain secreted by these clones reveals that it is indistinguishable in size from the syndecan-1 ectodomain that is shed from the surface of cells expressing wild-type syndecan-1 (Figure 2A). In addition, ACE18 was used to compare the collagen-binding affinity of the soluble syndecan-1 with that of soluble syndecan-1 ectodomain shed from cells transfected with full-length syndecan-1. Gels reveal that a low- and high-affinity fraction are present in both samples, and the high-affinity fraction in both samples shows a shift in proteoglycan mobility that occurs at a collagen concentration between 9 and 36 nM, with the Kd falling within that range (Figure 2B). Together, these results indicate that the proteoglycans made by cells transfected with the truncated syndecan-1 are similar in structure and affinity for ligands to the wild-type syndecan-1 ectodomain.
To determine if the soluble syndecan-1 ectodomain influences cell
growth in vitro, MTT assays were performed. No significant differences
in growth in vitro are detected between control cells and soluble
syndecan-1 clone sSyn1.10, whereas growth of clone sSyn-1.2 is somewhat
diminished by 72 hours (Figure 3). In
addition, the level of secreted immunoglobulin kappa light chain, an
indicator used to assess tumor burden in patients with myeloma, remains similar over time among the cell lines growing in vitro (data not
shown).
Soluble syndecan-1-expressing cells are hyperinvasive in vitro We have previously demonstrated that wild-type ARH-77 cells, which lack syndecan-1 expression, readily invade gels composed of type I collagen. Following transfection of these cells with the cDNA encoding the cell surface form of syndecan-1, the cells failed to invade.16 Therefore, we hypothesized that cells producing only soluble syndecan-1 ectodomain would not be inhibited from invading and would behave similarly to the syndecan-1-negative ARH-77 cells. However, surprisingly, cells producing soluble syndecan-1 ectodomain are hyperinvasive the percentage of invading cells is significantly
higher than cells lacking syndecan-1 expression and 6 times that of
cells that express syndecan-1 on their cell surface (Figure 4).
Soluble syndecan-1 promotes growth of tumors in SCID-hu mice Because a high concentration of soluble syndecan-1 ectodomain in the serum is an indicator of poor prognosis in patients with myeloma,10,11 we compared the in vivo growth and dissemination of ARH-77 cells that express either soluble syndecan-1 ectodomain or cell surface syndecan-1. An additional control included neo-transfected ARH-77 cells that lack syndecan-1 expression. These experiments were performed by using the SCID-hu model in which a fragment of human bone is implanted subcutaneously in each side of a SCID mouse. Although these experiments are very labor intensive, they provide an excellent model for studying the experimental growth of human tumors within a human marrow microenvironment. Several weeks after implantation of the bone, tumor cells were injected directly into the bone on the left side (primary tumor).20 At the conclusion of the experiment, the bone on the right side was analyzed for the presence of tumor cells as a measure of tumor dissemination (secondary tumor).15 Although injected directly into the bone, as the tumors enlarge, they often grow outside of the bone and surround the bone implant (Figure 5).
By manual palpation, tumors established with soluble syndecan-1
ectodomain-expressing cells were detected 4 to 5 weeks after injection
of cells into the bones, whereas tumors established by using wild-type
syndecan-1-expressing or neo-transfected cells were generally first
detected 5 to 6 weeks after injection. In initial experiments, animals
were killed 8 weeks after injection of tumor cells, and the level of
human kappa light chain, mean tumor diameter, and mean wet weight were
determined (Table 1). Results indicate
that cells expressing cell surface syndecan-1 form tumors poorly, with
only 1 in 5 animals having detectable levels of human light chain in
its serum. This finding is in contrast to neo-transfected and soluble
syndecan-1-expressing cells that are easily established within the
SCID-hu host. Although not statistically significant, measurements of
bone and associated tumor formed by soluble
syndecan-1-expressing cells have a greater mean diameter than do
controls. The lack of statistical significance may be due to the broad
variability in the initial size of bones and the shape of the resulting
tumors that usually overgrow the bone. Wet weight results are also
somewhat difficult to interpret because of differences in initial bone
weight and size between animals, and the extent to which bone is
degraded by the tumor. However, the mean weight of the bone and
associated tumor tissue from animals injected with soluble
syndecan-1-expressing cells was significantly greater than that of
tissue from animals injected with cells bearing cell surface
syndecan-1.
To quantitatively assess the rate of tumor growth within the marrow,
blood was collected biweekly and analyzed for the level of human kappa
light chain. Results reveal that the tumors producing soluble
syndecan-1 ectodomain grow at a significantly faster rate than tumors
lacking syndecan-1 expression (neo-transfectants) or tumors expressing
syndecan-1 at the cell surface (Figure
6). Results also indicate that cells
expressing syndecan-1 at their cell surface form tumors poorly in
SCID-hu mice, with 6 of the 14 animals having kappa levels below 1 µg/mL (Figure 7). However, when these
cells expressing cell surface syndecan-1 do form tumors, some of these
tumors grow significantly (4 of the 14 mice had kappa levels > 100
µg/mL). All animals injected with neo-transfected cells had
detectable levels of kappa in their serum, but only 4 of 13 mice had
kappa levels more than 100 µg/mL. In contrast, tumors formed in all
of the mice injected with soluble syndecan-1-expressing cells, and 13 of 15 had kappa levels more than 100 µg/mL. The mean kappa levels in
mice having soluble syndecan-1-expressing tumors are also
significantly higher than mean kappa levels of controls even when mice
that do not have detectable levels of kappa light chain are excluded
from the analysis (Figure 8). Together these data indicate that within the SCID-hu host, syndecan-1 at the
cell surface inhibits the establishment of the injected tumor cells,
whereas expression of soluble syndecan-1 promotes growth of the tumor.
Soluble syndecan-1 accumulates within the bone marrow interstitial matrix Recently, we have shown that soluble syndecan-1 accumulates within fibrotic regions of the bone marrow in some patients with myeloma.22 To determine if this accumulation occurs in the SCID-hu mice, we examined histologic sections of bone stained with antibody to syndecan-1. As expected, tumors established from neo-transfected cells show no staining for syndecan-1 within the interstitial matrix of the bone marrow (Figure 9). Tumors established from cells bearing cell surface syndecan-1 show extensive staining on the tumor cell surface but only very weak staining within adjacent interstitial matrix, indicating low levels of shed syndecan-1 are accumulating in these matrices. In contrast, the bone marrow interstitial matrix stains heavily in animals bearing tumors composed of soluble syndecan-1-expressing cells. This finding suggests that the soluble syndecan-1 becomes trapped within interstitial matrix of the bone marrow and accumulates at high levels, similar to what is observed in patients with myeloma.
Tumor cells disseminate to secondary bones in the SCID-hu mouse Finally, dissemination of the tumors to the secondary human bone and murine organs was assessed by flow cytometry or by kappa light chain immunohistochemistry of tissue sections (Figure 10). Dissemination of tumor was not detected in the mouse organs examined except in the livers of 2 mice bearing soluble syndecan-1-expressing tumors. However, by immunohistochemistry, 11 weeks after injection of tumor cells into the primary bone, dissemination was detected within the contralateral human bone implants in 3 of 6 mice (50%) bearing neo tumors, 1 of 7 mice (14%) bearing syndecan-1 tumors, and 6 of 8 mice (75%) bearing soluble syndecan-1-expressing tumors (syndecan-1 versus soluble syndecan-1, P < .03).
These results provide the first direct evidence that soluble syndecan-1 ectodomain promotes the growth of B-lymphoid tumors in vivo. Tumors formed by cells expressing soluble syndecan-1 ectodomain were detected earlier and grew more extensively over an 8-week period than did tumors expressing cell surface syndecan-1 or cells lacking expression of syndecan-1. The accelerated growth of soluble syndecan-1-expressing tumors was not due to selection of clones with an intrinsically faster rate of growth because in vitro studies demonstrate that these cells grow at a similar rate to control cells (Figure 3). Also, the presence of tumor cells in secondary bone was more prevalent in tumors formed by cells expressing soluble syndecan-1 ectodomain than in controls, suggesting that the soluble proteoglycan promotes the dissemination of tumor cells in addition to supporting their growth. Thus, we conclude that soluble syndecan-1 ectodomain may play an important role in regulating the behavior of B-lymphoid tumors in vivo. The finding that soluble syndecan-1 ectodomain promotes tumor growth in vivo is surprising in light of the previous in vitro observation that addition of exogenous ectodomain induces apoptosis of myeloma cells and inhibits the growth of carcinoma cells.13,14 One explanation for this difference may be that the exogenous syndecan-1 ectodomain is in high enough concentration to inhibit factors necessary for maintenance of the tumor cells in culture. Alternatively, the difference in syndecan-1 ectodomain influence in vitro and in vivo may be due to the way the molecule is processed once it is in the extracellular compartment. Processing of heparan sulfate chains by degradative enzymes can regulate the biologic activity of the soluble syndecan-1 ectodomain. For example, heparanase, an endoglycosidase that cleaves heparan sulfate chains,23,24 can regulate the activity of syndecan heparan sulfate. The intact syndecan-1 ectodomain binds to soluble FGF-2 and inhibits its growth-promoting activity. However, in the presence of heparanase, highly sulfated fragments are generated from the syndecan-1 heparan sulfate chains, and these fragments act to enhance the growth-promoting activity of FGF-2.9 Interestingly, Western blots of soluble syndecan-1 ectodomain isolated from the sera of patients with myeloma show very extensive heterogeneity of the proteoglycan, suggesting that indeed the heparan sulfate chains may be degraded in vivo.10 Although the mechanism for promotion of tumor growth by soluble syndecan-1 in vivo is unknown, it may be acting to retain heparin-binding factors within the marrow microenvironment that act to stimulate tumor growth and/or support tumor cell survival. This possibility is supported by the finding that syndecan-1 expression is required for Wnt-1-induced mammary tumorigenesis.25 It is likely that the soluble syndecan-1 ectodomain binds to insoluble extracellular molecules within the marrow such as type I collagen, a known ligand of syndecan-1.26 In patients with myeloma, high levels of shed syndecan-1 are present within the bone marrow, particularly within regions of marrow fibrosis,22 and by the present study in which high levels of soluble syndecan-1 are found trapped in the marrow microenvironment (Figure 9). In patients, this reservoir of syndecan-1 with bound growth factors within the bone marrow may promote disease relapse by nurturing residual tumor cells that survive chemotherapy. Conversely, the syndecan-1 may act by some unknown mechanism to inhibit tumor cell apoptosis, thereby promoting the rapid growth of the tumor. Another important finding of this work is that cells expressing cell surface syndecan-1 do not form tumors well in the SCID-hu host (Figure 7). This finding is consistent with previous studies showing that cells expressing syndecan-1 on their surface grow poorly in SCID mice following their introduction via tail vein injection.14 It was not known previously if this result using tail vein injection was due to the inability of syndecan-1-expressing cells to extravasate from the blood into the marrow, or if the cells simply did not grow well once in the marrow. Results from the present study, in which cells are injected directly into the bone, suggest that the cells expressing cell surface syndecan-1 do not form tumors as well as cells lacking surface syndecan-1. In the present study we have used either cells that express cell surface, soluble, or no syndecan-1 to dissect the relative effects of this molecule on tumor behavior. However, in most myeloma tumors, both cell surface syndecan-1 and shed syndecan-1 are present.11,12,22,27,28 Thus, it is now important to examine the effects of high levels of soluble syndecan-1 on myeloma cells that also express the proteoglycan on their cell surface. Analysis of tumor cell dissemination in vivo indicates that the cells expressing soluble syndecan-1 metastasize more extensively than cells bearing surface syndecan-1 or cells lacking syndecan-1 expression altogether. We cannot rule out the possibility that the higher dissemination rate seen with tumors formed from soluble syndecan-1-expressing cells is due to their faster growth. It is possible that high levels of syndecan-1 accumulating adjacent to the tumor cells concentrate factors that stimulate cell motility. Additionally, the high level of soluble syndecan-1 in the marrow matrix may coat other extracellular matrix molecules such as collagen and fibronectin, thereby blocking the binding of cells to these matrix ligands. The loosely attached cells could then more easily migrate away from the site of the primary tumor. It is interesting to note that in general we find that the tumors in the SCID-hu do not disseminate readily to murine organs. In contrast to that seen in SCID mice lacking human bone in which the ARH-77 cells often metastasize to murine organs, in the SCID-hu they home preferentially to the human bone and in general do not grow within the murine organs. Thus, the presence of human bones plays a determining role in regulating dissemination of the tumor cells. The finding that soluble syndecan-1 ectodomain promotes tumor growth in vivo is consistent with the observation that high levels of soluble syndecan-1 ectodomain in the serum of myeloma patients is an indicator of poor prognosis.11 Although it is not known if the soluble syndecan-1 in these patients plays an active role in promoting tumor growth or is simply a byproduct of a phenotypically aggressive tumor, our findings suggest that syndecan-1 does actually play an active role. Thus, therapies designed to block the shedding of syndecan-1 or to block the activity of shed syndecan-1 ectodomain may diminish tumor growth in patients with myeloma.
Submitted November 8, 2001; accepted March 10, 2002.
Supported by grants CA55819 and CA68494 from the National Cancer Institute.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ralph D. Sanderson, Department of Pathology, Slot 517, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205; e-mail: sandersonralphd{at}uams.edu.
1. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997;327:1-16[Medline] [Order article via Infotrieve]. 2. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777[CrossRef][Medline] [Order article via Infotrieve]. 3. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med. 1996;28:63-67[Medline] [Order article via Infotrieve]. 4. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001;12:89-98[CrossRef][Medline] [Order article via Infotrieve]. 5. Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000;88:12-20[CrossRef][Medline] [Order article via Infotrieve].
6.
Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD.
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.
Blood.
1993;81:767-774 7. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J. 1997;321:265-279[Medline] [Order article via Infotrieve].
8.
Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M.
Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.
J Cell Biol.
2000;148:811-824 9. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med. 1998;4:691-697[CrossRef][Medline] [Order article via Infotrieve]. 10. Dhodapkar MV, Kelly T, Theus A, Athotha AP, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Hematol. 1997;99:368-371[CrossRef][Medline] [Order article via Infotrieve].
11.
Seidel C, Sundan A, Hjorth M, et al.
Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Blood.
2000;95:388-392
12.
Seidel C, Borset M, Hjertner O, et al.
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.
Blood.
2000;96:3139-3146
13.
Mali M, Andtfolk H, Miettinen HM, Jalkanen M.
Suppression of tumor cell growth by syndecan-1 ectodomain.
J Biol Chem.
1994;269:27795-27798
14.
Dhodapkar MV, Abe EA, Theus A, et al.
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone cell differentiation.
Blood.
1998;91:2679-2688
15.
Urashima M, Chen BP, Chen S, et al.
The development of a model for the homing of multiple myeloma cells to human bone marrow.
Blood.
1997;90:754-765
16.
Liebersbach BF, Sanderson RD.
Expression of syndecan-1 inhibits cell invasion into type I collagen.
J Biol Chem.
1994;269:20013-20019 17. Pieters R, Huismans DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett. 1988;41:323-332[CrossRef][Medline] [Order article via Infotrieve].
18.
Langford JK, Stanley MJ, Cao D, Sanderson RD.
Multiple heparan sulfate chains are required for optimal syndecan-1 function.
J Biol Chem.
1998;273:29965-29971
19.
Namikawa R, Ueda R, Kyoizumi S.
Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
Blood.
1993;82:2526-2536
20.
Yaccoby S, Barlogie B, Epstein J.
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
Blood.
1998;92:2908-2913
21.
Jalkanen M, Nguyen H, Rapraeger A, Kurn N, Bernfield M.
Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody.
J Cell Biol.
1985;101:976-984 22. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Ownes RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14:1052-1058[CrossRef][Medline] [Order article via Infotrieve]. 23. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999;5:793-802[CrossRef][Medline] [Order article via Infotrieve]. 24. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med. 1999;5:803-809[CrossRef][Medline] [Order article via Infotrieve]. 25. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000;25:329-332[CrossRef][Medline] [Order article via Infotrieve]. 26. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD. Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecan. J Immunol. 1992;148:3902-3911[Abstract]. 27. Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1998;31:167-175[Medline] [Order article via Infotrieve]. 28. Costes V, Magen V, Legouffe E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999;30:1405-1411[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hayashida, P. D. Stahl, and P. W. Park Syndecan-1 Ectodomain Shedding Is Regulated by the Small GTPase Rab5 J. Biol. Chem., December 19, 2008; 283(51): 35435 - 35444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma J. Biol. Chem., November 21, 2008; 283(47): 32628 - 32636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Su, S. A. Blaine, D. Qiao, and A. Friedl Membrane Type 1 Matrix Metalloproteinase-Mediated Stromal Syndecan-1 Shedding Stimulates Breast Carcinoma Cell Proliferation Cancer Res., November 15, 2008; 68(22): 9558 - 9565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hayashida, Y. Chen, A. H. Bartlett, and P. W. Park Syndecan-1 Is an in Vivo Suppressor of Gram-positive Toxic Shock J. Biol. Chem., July 18, 2008; 283(29): 19895 - 19903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy Blood, September 15, 2007; 110(6): 2041 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mahtouk, D. Hose, P. Raynaud, M. Hundemer, M. Jourdan, E. Jourdan, V. Pantesco, M. Baudard, J. De Vos, M. Larroque, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma Blood, June 1, 2007; 109(11): 4914 - 4923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Su, S. A. Blaine, D. Qiao, and A. Friedl Shedding of Syndecan-1 by Stromal Fibroblasts Stimulates Human Breast Cancer Cell Proliferation via FGF2 Activation J. Biol. Chem., May 18, 2007; 282(20): 14906 - 14915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yang, V. MacLeod, H.-Q. Miao, A. Theus, F. Zhan, J. D. Shaughnessy Jr., J. Sawyer, J.-P. Li, E. Zcharia, I. Vlodavsky, et al. Heparanase Enhances Syndecan-1 Shedding: A NOVEL MECHANISM FOR STIMULATION OF TUMOR GROWTH AND METASTASIS J. Biol. Chem., May 4, 2007; 282(18): 13326 - 13333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Fears, C. L. Gladson, and A. Woods Syndecan-2 Is Expressed in the Microvasculature of Gliomas and Regulates Angiogenic Processes in Microvascular Endothelial Cells J. Biol. Chem., May 26, 2006; 281(21): 14533 - 14536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Selleck Shedding Light on the Distinct Functions of Proteoglycans Sci. Signal., April 4, 2006; 2006(329): pe17 - pe17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, Y. Yang, V. MacLeod, X. Yue, A. C. Rapraeger, Z. Shriver, G. Venkataraman, R. Sasisekharan, and R. D. Sanderson HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo J. Biol. Chem., December 2, 2005; 280(48): 40066 - 40073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ding, M. Lopez-Burks, J. A. Sanchez-Duran, M. Korc, and A. D. Lander Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells J. Cell Biol., November 21, 2005; 171(4): 729 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yang, V. MacLeod, M. Bendre, Y. Huang, A. M. Theus, H.-Q. Miao, P. Kussie, S. Yaccoby, J. Epstein, L. J. Suva, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone Blood, February 1, 2005; 105(3): 1303 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Reiland, R. D. Sanderson, M. Waguespack, S. A. Barker, R. Long, D. D. Carson, and D. Marchetti Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate: FUNCTIONAL IMPLICATIONS FOR TUMOR CELL INVASION J. Biol. Chem., February 27, 2004; 279(9): 8047 - 8055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maeda, C. M. Alexander, and A. Friedl Induction of Syndecan-1 Expression in Stromal Fibroblasts Promotes Proliferation of Human Breast Cancer Cells Cancer Res., January 15, 2004; 64(2): 612 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kelly, H.-Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, et al. High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density Cancer Res., December 15, 2003; 63(24): 8749 - 8756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Underhill, K. P. Kolli, and G. S. Kansas Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation Blood, December 1, 2003; 102(12): 4076 - 4083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Asosingh, H. De Raeve, I. Van Riet, B. Van Camp, and K. Vanderkerken Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis Blood, April 15, 2003; 101(8): 3136 - 3141. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
